Skip to main content

TableĀ 1 Cost per DALY averted considering higher malaria testing and treatment rates

From: Economic considerations support C-reactive protein testing alongside malaria rapid diagnostic tests to guide antimicrobial therapy for patients with febrile illness in settings with low malaria endemicity

Ā 

Introduction of treatment for NMFIs

Before

After

Sources/estimation/comments

A

Median village population

768

McLean [17]

B

Monthly malaria tests carried out

15.0

34.9

McLean [17]

C

% testing positive for malaria

9.2%

6.0%

McLean [17]

D

Monthly incidence NMFI (regional average)

38.4

Capeding [42]

E

Monthly incidence malaria

3.9

2.4

(Dā€‰*ā€‰C)/(1ā€‰āˆ’ā€‰C)

F

Total incidence febrile illness

42.3

40.8

Dā€‰+ā€‰E

G

Probability febrile patient attends CHW

35%

86%

B/F

H

Treated malaria cases

1.4

2.1

Bā€‰*ā€‰C

I

Untreated malaria cases

2.5

0.4

Eā€‰āˆ’ā€‰F

J

Untreated malaria cases averted

Ā 

2.2

āˆ†I

K

Mortality rate in untreated malaria

1%

Lubell [36]

L

Monthly malaria mortality averted per village

Ā 

0.029

Jā€‰*ā€‰K

M

Years of life lost per death

45

Assumption

N

DALYs averted

Ā 

0.97

Lā€‰*ā€‰M

O

Cost per CRP test

$1

CRP test costs are as low as $0.5; additional costs of transport, storage and training included here

P

Incremental cost per month

Ā 

$ 35

0*B2

Ā 

ICER (cost per DALY averted)

Ā 

$ 36

P/N